Logo

ViiV Healthcare Reports Results of Fostemsavir in P-III BRIGHTE Study for HIV-1 infection

Share this

ViiV Healthcare Reports Results of Fostemsavir in P-III BRIGHTE Study for HIV-1 infection

Shots:

  • The P-III BRIGHTE study involves assessing of fostemsavir + OBT vs PBO in 371 patients in a ratio (3:1) with HIV-1 infection who were resistant- intolerable and contraindicated to all ARV in at least four ARV classes
  • The P-III BRIGHTE study resulted in increased rates of virologic suppression and immunologic response from 48wks. to 96wks.- @96wks. increase in CD4+ T-cell counts- 67% patients showed CD4 <200 cells/µL to a CD4 ≥200 cells/µL- 56% patients showed CD4 <50 cells/µL increased to a CD4 ≥200 cells/µL
  • Fostemsavir is a prodrug of temsavir that binds to the gp120 subunit within the HIV-1 envelope glycoprotein gp160 complex thus preventing the interaction between the virus and cellular CD4 receptors with its expected NDA submission in H2’19

Click here to read full press release/ article | Ref: GSK | Image: POZ


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions